It would seem reasonable to investigate the possibility of a relationship between HER2 status and response to anti-EGFR therapy in patients with breast cancer as well, based on our findings in breast cancer cell lines that responses to trastuzumab and AG1478 alone or in combination are correlated with high levels of HER2 expression. Here, EGFR is linked to breast carcinoma.